DUBLIN, November 21, 2022 /PRNewswire/ — The “Digital Marketing Trends in Severe Asthma” the report has been added to the ResearchAndMarkets.com offering.
Sanofi/Regeneron’s Dupixent.com achieved the highest traffic on branded severe asthma patient sites in the US since July 2021 a June 2022with around 7,800,000 hits, followed by Novartis’ Xolair.com and GSK’s Nucala.com.
The highest proportion of traffic to these sites originated from direct sources, followed by organic searches. Amgen/AstraZeneca’s Tezspire.com had the highest amount of direct traffic (83%), while the remaining brands, Dupixent, Cinqair, Nucala and Xolair, had levels between 52 and 66%.
For patient brand sites, Sanofi/Regeneron spent more on DDA for Dupixent.com by approx. 4.2 million dollarsfollowed by GSK’s Nucala.com at approx $900,000. Dupixent.com was supported by the highest paid keywords with approximately 10,650 keywords, followed by Tezspire.com with approximately 5,800 keywords.
For branded HCP sites in the US, Sanofi/Regeneron’s Dupixenthcp.com had the highest number of visits with approximately 775,000 total visits, followed by AstraZeneca’s Fasenrahcp.com and GSK’s Nucalahcp.com. The highest proportion of traffic to these sites originated from direct sources, followed by organic and referral sources.
Teva’s Cinqairhcp.com had the highest proportion of direct search traffic (81%). Sanofi/Regeneron spent more on DDA for Dupixenthcp.com approx $51,400followed by Amgen/AstraZeneca’s Tezspirehcp.com at approx $17,100.
Between July 2021 i June 2022, the top 20 asthma social media posts by pharmacy interaction were from the Sanofi Facebook, Genentech Instagram, Regeneron Instagram, Fasenra Facebook, and GSK Instagram accounts. AstraZeneca’s Vik Asthma is the only drugstore-detected severe asthma app in the US, with an estimated 30,700 downloads in 2021.
Most of the branded websites in EUCAN are patient oriented and few have generated significant traffic from each other July 2021 i June 2022. Sanofi/Regeneron’s Dupixentmyway.co.uk and Dupixent.co.uk achieved the highest traffic, with around 20,200 and 3,400 hits respectively.
Between July 2021 i June 2022, eight of the top 20 asthma social media posts by pharma EUCAN interaction were from AstraZeneca Espana’s Instagram account. No pharmacy asthma mobile apps detected in EUCAN.
This report evaluates key digital marketing metrics for pharmaceutical assets in severe asthma, including branded patient and healthcare professional (HCP) websites, mobile apps and social media accounts. Metrics include website traffic volume, engagement and source, digital display advertising (DDA), paid search engine optimization (SEO), mobile app downloads and post engagement in social networks. Countries include the US, 4EU (Italy, France, Germanyi Spain), the United Kingdom and canada (EUCAN).
Reasons to buy
Understand the competitive landscape of digital marketing in severe asthma, with a view of the main brand assets of patients and healthcare professionals in different regions. See what tactics pharmaceutical companies are using to drive traffic to their severe asthma brand assets for patients and healthcare professionals, including DDA and paid SEO. Understand which website traffic sources drive the most visits to these assets, such as paid SEO, social media, or organic search. Compare the most important brand assets for patients based on how they address and support different patient needs. See which severe asthma pharma social media accounts are the most active and get the most engagement. Check out the top severe asthma mobile app deals from pharmacies in different regions.
Key topics covered:
Executive Summary US Patient Branded Websites US HCP Branded Websites US Digital Display Advertising and Search Engine Optimization US Mobile Apps & Social Media EUCAN Branded Websites EUCAN Mobile Apps & Social Media Appendix
Sanofi Regeneron Genentech Novartis GSK AstraZeneca Amgen Teva
Contact with the media:
Research and Markets
Laura WoodSenior Manager
For EST office hours, call +1-917-300-0470
For US/CAN call toll free at +1-800-526-8630
For GMT office hours, call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716
SOURCE Research and markets